8/1/2014 8:56:45 AM
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter ended June 30, 2014. As of June 30, 2014, GlycoMimetics had cash and cash equivalents of $66.2 million, which reflects the company’s net proceeds of $57.2 million from its January 2014 initial public offering (IPO) and a $15.0 million non-refundable milestone payment received from Pfizer in May 2014 under the parties’ collaboration for the drug candidate rivipansel (previously known as GMI-1070).
Help employers find you! Check out all the jobs and post your resume.
comments powered by